Targeting the technology and healthcare sectors, private equity funds frequently conduct research.

The technology and pharmaceutical sectors are becoming the "battleground" for private equity investments. According to the latest data from Private Equity Rappai Network, in June, private securities investment fund managers researched a total of 387 listed companies, totaling 1769 research visits. In terms of industries, private equity firms favor sectors such as electronics, pharmaceuticals and biotechnology, and mechanical equipment. At the same time, many top private equity firms have revealed that they are focusing on technology and innovative pharmaceutical targets. In the view of industry insiders, as the effects of policies gradually become apparent, global funds are increasing their allocations to Chinese assets, and structural opportunities in A-shares and Hong Kong stocks will continue to emerge, especially for high-quality enterprises in the technology and pharmaceutical sectors, which may experience a "Davis double-click" (a term referring to stocks that outperform the market twice). Therefore, now is a good time for "aiming and shooting".